0RU9 Stock Chart & Stats
€754.80
€0.00(0.00%)
At close: 4:00 PM EDT
€754.80
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€754.80 - €754.80
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€11.28M
Enterprise Value€3.34
Total Cash (Recent Filing)€8.92M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
BetaN/A
Next Earnings
Aug 12, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.46
Shares Outstanding44,338,573
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.75
Price to Sales (P/S)0.00
P/FCF Ratio-0.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.3
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage (no Debt)Zero reported debt materially reduces balance-sheet risk and interest burden, providing structural financial flexibility. For a clinical-stage biotech this lowers near-term solvency pressure and gives management more runway to prioritize R&D or selective financings without heavy fixed-cost obligations.
Platform-focused NK Cell Engager PipelineA focused, platform-based approach (TriKE and NK-engaging constructs) is a durable strategic asset: it supports multiple programs across indications, concentrates scientific expertise, and can generate repeat-value if clinical signals emerge, making long-term upside linked to platform validation.
Recovered Stockholders' EquityRestoration of positive equity indicates successful capital raises or retained financing that improved solvency versus the prior year. This structural improvement reduces immediate insolvency risk and suggests an ability to attract incremental funding to support ongoing clinical development.
Bears Say
Pre-revenue With Widening Net LossesBeing pre-revenue with increasing net losses is a persistent fundamental constraint: the company lacks operating cash inflows to fund activities, raising reliance on external capital. Over months this elevates execution and dilution risk if clinical milestones stall or financing conditions tighten.
Consistent Negative Operating Cash Flow (cash Burn)Sustained negative operating and free cash flow signals continuous cash consumption to fund R&D and operations. This structural cash burn necessitates recurring capital raises, constrains strategic optionality, and can pressure program timelines or force dilutive financings absent material clinical progress.
Governance / Shareholder Engagement ConcernsLowering the quorum requirement reflects persistent shareholder participation challenges and weaker governance engagement. Structurally, this can reduce shareholder oversight and make governance outcomes easier for management to enact, potentially heightening agency risk over multi-month horizons.
GT Biopharma News
0RU9 FAQ
What was GT Biopharma’s price range in the past 12 months?
GT Biopharma lowest share price was €754.80 and its highest was €754.80 in the past 12 months.
What is GT Biopharma’s market cap?
GT Biopharma’s market cap is €11.28M.
When is GT Biopharma’s upcoming earnings report date?
GT Biopharma’s upcoming earnings report date is Aug 12, 2026 which is in 4 days.
How were GT Biopharma’s earnings last quarter?
GT Biopharma released its earnings results on May 18, 2026. The company reported -€0.095 earnings per share for the quarter, the consensus estimate of -€0.095 by €0.
Is GT Biopharma overvalued?
According to Wall Street analysts GT Biopharma’s price is currently Overvalued.
Does GT Biopharma pay dividends?
GT Biopharma does not currently pay dividends.
What is GT Biopharma’s EPS estimate?
GT Biopharma’s EPS estimate is -0.07.
How many shares outstanding does GT Biopharma have?
GT Biopharma has 44,338,573 shares outstanding.
What happened to GT Biopharma’s price movement after its last earnings report?
GT Biopharma reported an EPS of -€0.095 in its last earnings report, expectations of -€0.095. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of GT Biopharma?
Currently, no hedge funds are holding shares in GB:0RU9
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
GT Biopharma
GT Biopharma, Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and bringing to market novel immuno-oncology treatments. Their innovative approach centers on a proprietary technology platform called Tri-specific Killer Engager (TriKE) fusion proteins, which are designed to harness the body's immune cells. Central to their pipeline is GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate currently undergoing Phase I/II clinical trials. This therapeutic candidate is being evaluated for its potential in treating myelodysplastic syndromes, acute myeloid leukemia that has relapsed or proven refractory to prior treatments, advanced systemic mastocytosis, and other malignancies expressing CD33. The company's research also includes GTB-3650, which is in preclinical development targeting CD33 on myeloid leukemias, and GTB-5550, another preclinical asset aimed at solid tumors that are positive for B7-H3. GT Biopharma has forged key collaborations, including a co-development agreement with Altor BioScience Corporation for the clinical advancement of a 161533 TriKE fusion protein for various cancer indications. Furthermore, they maintain a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies utilizing their TriKE technology. Founded in 1965, the company previously operated as OXIS International, Inc. before rebranding to GT Biopharma, Inc. in July 2017. Its corporate operations are based in Brisbane, California.
Technical Analysis
Theriva Biologics
―
Revelation Biosciences
―
Dermata Therapeutics
―
CERo Therapeutics Holdings
―
Azitra Inc
―